title: Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
abstract: OBJECTIVE
  To analyze the prognosis and outcomes of patients who remain free of biochemical failure during the first 5 years after treatment.
  
  
  METHODS
  Between 1991 and 2002, 742 patients with prostate cancer were treated with brachytherapy alone (n = 306), brachytherapy and hormonal therapy (n = 212), or combined implantation and external beam radiotherapy (with or without hormonal therapy; n = 224). These patients were free of biochemical failure (American Society for Therapeutic Radiology and Oncology [ASTRO] definition) during the first 5 post-treatment years and had a documented 5-year prostate-specific antigen (PSA) value. The median follow-up was 6.93 years.
  
  
  RESULTS
  The actuarial 10-year freedom from PSA failure rate was 97% using the ASTRO definition and 95% using the Phoenix definition. The median 5-year PSA level was 0.03 ng/mL (range, 0-3.6). The 5-year PSA value was <or=0.01 in 47.7%, >0.01-0.10 in 31.1%, >0.10-0.2 in 10.2%, >0.2-0.5 in 7.82%, and >0.5 in 3.10%. The 5-year PSA value had prognostic significance, with a PSA value of <or=0.2 ng/mL (n = 661) corresponding to a 10-year freedom from PSA failure rate of 99% with the ASTRO definition and 98% with the Phoenix definition vs. 86% (ASTRO definition) and 81% (Phoenix definition) for a PSA value >or=0.2 ng/mL (n = 81; p < .0001). The treatment regimen had no effect on biochemical failure. None of the 742 patients in this study developed metastatic disease or died of prostate cancer.
  
  
  CONCLUSIONS
  The results of this study have shown that the prognosis for patients treated with brachytherapy and who remain biochemically free of disease for >or=5 years is excellent and none developed metastatic disease during the first 10 years after treatment. The 5-year PSA value is prognostic, and patients with a PSA value <0.2 ng/mL are unlikely to develop subsequent biochemical relapse.
authors.affiliation: Department of Radiation Oncology, Mount Sinai Hospital, New York, NY 10029, USA. Richard.stock@mountsinai.org
authors.forename: Richard G
authors.initials: RG
authors.lastname: Stock
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Klein
authors.forename: Jamie A
authors.initials: JA
authors.lastname: Cesaretti
authors.forename: Nelson N
authors.initials: NN
authors.lastname: Stone
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D011878:Radiotherapy / Q000379:methods; D011879:Radiotherapy Dosage; D012016:Reference Values; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen